INTERNATIONAL BIOTECHNOLOGY TRUST PLC (the Company)
Portfolio Update as at 30 November 2017
Net Assets |
£227m |
Net Assets per share |
603p |
Share price |
609p |
Total value of unquoted investments |
£19m |
Total number of portfolio companies |
93 |
Dividend |
4% of NAV per annum |
Top Ten Quoted Investments
Company Name |
% NAV |
Biogen |
7.5 |
Celgene |
5.4 |
Adamas |
5.3 |
Regeneron |
4.8 |
Nektar |
4.0 |
Vertex |
4.0 |
Exelixis |
3.9 |
Acadia |
3.3 |
Gilead |
3.0 |
Genmab |
2.9 |
|
----------- |
Total |
44.1 |
Geographical Allocation |
% NAV |
US & Canada |
90 |
Europe & UK |
10 |
|
----------- |
Total |
100 |
Quoted/Unquoted Allocation |
% NAV |
Quoted |
92 |
Unquoted |
8 |
|
----------- |
Total |
100 |
NAV % Market Cap |
% NAV |
Large Cap >USD10BN |
28 |
Mid Cap =USD1-10BN |
36 |
Small Cap <USD1BN |
36 |
|
----------- |
Total |
100 |
NAV % by Therapeutic Areas |
% NAV |
Oncology |
40 |
CNS |
13 |
Rare diseases |
11 |
Inflammation |
8 |
Ophthalmology |
7 |
Infectious Diseases |
6 |
Metabolic |
4 |
Medtech |
2 |
Other |
9 |
|
----------- |
Total |
100 |
BNP Paribas Secretarial Services Limited
Company Secretary
20 DECEMBER 2017